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Abstract: Solitary plasmacytoma is an infrequent form of plasma cell dyscrasia that presents as a single mass of
monoclonal plasma cells, located either extramedullary or intraosseous. In some patients, a bone marrow aspiration
can detect a low monoclonal plasma cell infiltration which indicates a high risk of early progression to an overt
myeloma disease. Before treatment initiation, whole body positron emission tomography–computed tomography
or magnetic resonance imaging should be performed to exclude the presence of additional malignant lesions. For
decades, treatment has been based on high-dose radiation, but studies exploring the potential benefit of systemic
therapies for high-risk patients are urgently needed. In this review, a panel of expert European hematologists updates
the recommendations on the diagnosis and management of patients with solitary plasmacytoma.
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Background
Plasma cell (PC) neoplasms can present in different clin-
ical forms. Multiple myeloma (MM) is generally located
in the bone marrow (BM) and associated with a wide
spectrum of clinical, laboratory, and radiological findings
[1]. Conversely, solitary plasmacytoma (SP) is character-
ized by a single mass of clonal plasma cells, with no or
minimal BM plasmacytosis and with no other symptoms
than those derived from the primary lesion. It can
present either as extramedullary (extraosseous) plasma-
cytoma (EMP), i.e., in soft tissues, or as solitary bone
plasmacytoma (SBP). SP is a rare condition with a cu-
mulative incidence of 0.15/100.000 [2]. Liebross et al.
reported that out of 1354 patients treated for plasma cell
neoplasms at the MD Anderson Cancer Center between
1963 and 1996, 1272 patients (94%) had MM, 60 pa-
tients (4%) had SBP, and 22 patients (2%) had EMP [3].
A recent Swedish population study showed a similar dis-
tribution of patients, with a global incidence of 0.191/
100.000 for male and 0.090/100.000 for female patients
[4]. SBP comprises 70% of all SP cases and occurs pri-
marily in red marrow-containing bones such as verte-
brae, femurs, pelvis, and ribs. EMP can involve any site
or organ, with the most frequent being the head and
neck region (sinuses, naso- and oropharynx), gastro-
intestinal tract, and lungs [3, 5]. Patients presenting with
SBP, especially those cases with minimal BM plasmacy-
tosis, have a higher risk of developing symptomatic MM:
approximately 50% of patients with SBP and 30% of
patients with EMP develop MM within 10 years after
the initial diagnosis [6]. Here, we provide a consensus
statement on the diagnostic criteria, prognostic factors,
treatment, and response criteria for SP. Readers should
be aware that the management of patients with localized
or solitary plasmacytomas is different from patients with
soft-tissue plasmacytomas in the context of overt
multiple myeloma.
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Methodology
These guidelines were developed by a working group of
clinical hematologists with expertise in MM. Literature
review was performed up to September 2017 and in-
cluded published clinical studies, meta-analyses and re-
views (Medline), and abstracts from the American
Society of Hematology (ASH) and European Hematology
Association annual meetings (keywords: plasmacytoma,
solitary, myeloma, PET/CT, MRI, radiotherapy, diagno-
sis, and treatment). Key recommendations were devel-
oped based on randomized, controlled clinical trial
evidence. If data were insufficient, expert consensus was
used to suggest recommendations. The drafted recom-
mendations were circulated among the working group
members who all provided comments. In addition, the
recommendations were discussed by working group
members at the International Myeloma Working Group
(IMWG), European Myeloma Network (EMN), and
ASH meetings. After three rounds of revisions, all work-
ing group members reviewed and validated the final
recommendations which were assigned using the GRADE
criteria, which incorporate recommendation strength and
quality of evidence (Additional file 1: Table S1).
Definition and diagnostic criteria
The advent of more sensitive techniques to assess BM
plasmacytosis has recently led to an updated definition
of SP by the IMWG [1]. SPB is defined by the presence
of a single lytic lesion due to monoclonal PC infiltration,
with or without soft-tissue extension, and EMP consists
of a soft-tissue mass that is not in contact with bone [7].
Accordingly, conventional morphology or immunohisto-
chemistry typically show no BM plasmacytosis, but min-
imal BM infiltration by clonal plasma cells (PCs < 10%)
was still considered consistent with a SP diagnosis, pro-
vided that no other lesions are observed (Table 1).
SP diagnosis is currently based on a tissue biopsy and
histological and immunohistochemical confirmation of
the presence of a homogenous infiltrate of monoclonal
plasma cells, which typically express CD138 and/or
CD38. Monoclonality needs to be proven by kappa/
lambda light chain restriction or by a PCR-based ap-
proach. Cytogenetic analysis of the SP generally identi-
fies the abnormalities that are frequently encountered in
MM. Interphase fluorescence in situ hybridization
(FISH) was realized in 2 small studies on EMP and iden-
tified a high incidence of 13q losses (ranging from 33 to
40%), IGH rearrangements (in about 37 to 53%), and
hyperdiploidy in 54% of the cases [8, 9]. However, no
prognostic correlation could be found between chromo-
somal aberrations and clinical features or disease
progression [8].
Two independent studies detected low levels of clonal
PCs in the BM by using more sensitive methods (i.e.,
flow cytometry) [10, 11]. Hill et al. demonstrated in 50
patients with SBP that occult BM disease, defined as a
discrete population of phenotypically aberrant PCs, is
present at diagnosis in 68% of patients. Importantly, the
presence of such aberrant cells had prognostic signifi-
cance, since progression to symptomatic MM or a new
plasmacytoma outside the irradiation field was docu-
mented in 72% (26/34) of these patients with occult
disease vs. 12.5% (2/16) in patients without and the me-
dian time to progression was 26 months vs. not reached.
Furthermore, Paiva et al. reported that 17 of 35 (49%) of
patients with SBP had aberrant BMPCs [11]. Of interest,
71% of patients with positive flow cytometry evolved to
MM vs. only 8% of those with negative flow. This
suggests that flow cytometry may be helpful in the dis-
tinction of the true SBP (negative flow cytometry) with a
very low rate of evolution to MM from those with high
risk of progression to myeloma (positive flow cytometry).
Both studies confirm that SP patients with minimal BM
plasmacytosis have an increased risk of progression to
MM compared to patients without BM involvement and
close attention should be given to the former group
during routine follow-up.
Finally, there is a small but well-recognized group of
patients characterized by multiple lytic bone lesions and
low BM plasmacytosis, the so-called macrofocal form of
Table 1 Diagnostic criteria for solitary plasmacytoma and overlapping disorders
Plasmacytoma Serum monoclonal
protein
Bone marrow
cytology
End organ
damage
Radiological
work-up
Risk of progression
Solitary
plasmacytoma
Solitary plasmacytoma Present Not required Negative No other lesions 10% will progress
to MM within 3 years
Solitary plasmacytoma
with minimal bone
marrow involvement
Present Not required Monoclonal PC
infiltration < 10%
Absent No other lesions 60% with SBP
or 20% with EMP
will progress
to MM within 3 years
Multiple
myeloma
Macrofocal myeloma Present Not required Monoclonal PC
infiltration < 10%
Possible Multiple lesions
Multiple myeloma Not required Present Monoclonal PC
infiltration ≥ 10%
Present Other lesions
could be present
Abbreviations: MM multiple myeloma, BM bone marrow, PC plasma cell, EMP extrameddulary plasmacytoma
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MM [12]. These patients are generally younger than the
overall myeloma population and have a better prognosis.
Bone marrow assessment
A unilateral BM aspiration and trephine biopsy is rec-
ommended for all patients with suspected SP. In order
to exclude > 10% of monoclonal PCs in the BM, a BM
aspiration with immunophenotyping to define the pro-
portion of monoclonal cells by kappa/lambda labeling
should be performed. When the possibility for immuno-
phenotyping is missing, a BM biopsy is recommended
with immunohistochemistry to detect monoclonal PCs.
A biopsy might reveal more monoclonal cells because of
a sampling error with aspiration. The higher PC count
of either aspiration or biopsy should be considered in
cases of discrepancy between both techniques.
Noteworthy, the malignant phenotype of clonal PCs
among patients with SP resembles that of cases with
MM; accordingly, we recommend that laboratories use
the same immunophenotypic strategy used in MM such
as that established by the EuroFlow consortium for the
assessment of minimal residual disease (MRD), which
has a median limit of tumor cell detection of 2 × 10−6,
and is virtually applicable to all patients with PC dyscra-
sias [13]. BM plasmacytosis > 10% constitutes a definitive
MM diagnosis.
Recommendations: All patients with suspected SP
should receive a BM aspiration and a BM biopsy to evalu-
ate PC morphology and the degree of total PC infiltration
(Grade 1A). Given the diagnostic and prognostic import-
ance, the degree of clonal PC infiltration should be deter-
mined by flow cytometry or by kappa/lambda labeling on
the BM aspirate or by immunohistochemistry on a BM bi-
opsy (Grade 1B). When a monoclonal PC infiltration is
present at baseline, the BM aspiration and biopsy should
be repeated when a progression to MM is suspected.
Imaging
Detection and localization of SP depends on imaging
studies. In addition, since SP is defined by the absence
of other bone or extramedullary lesions, imaging is
required to exclude a MM diagnosis.
Conventional radiography of the skeleton and computed
tomography
Conventional radiography of the skeleton (skeletal sur-
vey) has been recommended for the initial assessment of
bone lesions for decades. SBP preferentially replaces the
trabecular bone, while the cortical bone is partly
conserved or even sclerotic [14]. In two thirds of the
cases, the radiographic appearance is characteristic with
a mixed, predominantly lytic pattern. Less commonly,
SBP has a multicystic appearance. Similar to in MM
patients, skeletal surveys are not sensitive enough to
detect early lytic bone lesions which are only visible
when more than 30% of cortical bone is destructed [15,
16]. Moreover, conventional X-ray imaging does not
reveal EMP located in soft tissues. This underlines the
need for other imaging techniques for the evaluation of
skeletal and extramedullary lesions, i.e., computed tom-
ography (CT), magnetic resonance imaging (MRI), and
positron emission tomography (PET)/CT.
In the context of EMP, CT may be helpful for an
adequate loco-regional staging as regional lymph node
recurrences occur in 7% of EMP cases. CT can also be
used to identify spinal cord and/or nerve root compres-
sion when MRI is unavailable. Importantly, compression
due to a soft tissue mass may be missed on CT scans
without contrast injection [15]. Whole-body (WB)-CT
provides high-resolution images of cortical and trabecu-
lar bone with a fast scanning time and it is able to detect
small (< 5 mm) lytic bone lesions [17–21]. Clinical stud-
ies addressing the use of WB-CT in comparison with
other imaging techniques for SP are currently lacking.
Low-dose WB-CT is currently proposed as the initial
imaging technique of choice to detect bone disease in
patients with MM [22].
Magnetic resonance imaging (MRI)
Although the sensitivity of MRI to detect lytic bone le-
sions is lower than that of CT, MRI is able to detect soft
tissue and BM lesions and is the gold standard to detect
spinal cord compression. SBP appears as an infiltration
with a low T1 and a high T2 signal intensity. Moulopoulos
et al. prospectively studied the role of MRI in the staging
of 12 patients with SBP [23]. In order to identify other
regions of BM involvement in addition to the primary SBP
lesion, patients underwent spinal MRI. Additional foci of
marrow replacement were found in one third of patients,
and these patients showed persistent elevated serum
monoclonal protein levels after radiotherapy. Conversely,
patients without additional BM lesions displayed a signifi-
cant reduction or disappearance of serum monoclonal
protein after radiotherapy [23]. Liebross et al. confirmed
these results in a second study in which 57 patients with
SBP were staged with either conventional radiography
alone or in combination with MRI prior to radiotherapy
[24]. Among 23 patients with thoracolumbar spine
disease, 7 of 8 patients, who had a solitary lesion by
plain radiographs alone, developed MM in compari-
son with 1 of 7 patients who also had only one lesion
by MRI. Together, these prospective studies underline
the importance of precise staging. Consequently, ex-
cluding additional lesions is mandatory for the diag-
nosis of SP as per IMWG criteria [25]. The use of
diffusion-weighted MRI, a new highly sensitive tech-
nique to detect and monitor tumor lesions in the BM
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and soft tissues, has not been reported in the
management of SP.
Positron emission tomography/computed tomography
(PET/CT)
While 18F-FDG (fluorine-18-fludeoxyglucose) PET/CT
is extensively studied in MM, only a few small-scale
studies have addressed its role in SP [26]. 18F-FDG PET
or 18F-FDG PET/CT may show additional lesions and
have therapeutic implications in 33–55% of patients with
presumed SBP as patients with a normal PET/CT did
not develop MM [27–29]. Salaun et al. reported that
18F-FDG PET/CT is superior to MRI for the diagnosis
and follow-up of plasmacytoma patients, although it
should be noted that this study was performed in the
context of extramedullary spread during MM [30]. At
diagnosis, the sensitivity and specificity of PET/CT was
higher than that of MRI of the spine and pelvis, because
PET/CT was able to detect plasmacytoma lesions with a
larger scope compared to MRI, i.e., in soft tissues, skull,
ribs, and limbs. Also, the specificity of PET/CT was 99%
to evaluate treatment responses, compared to 89% for
MRI. A second study evaluated PET/CT and axial MRI
at diagnosis and follow-up in 43 patients with either
EMP (10 patients) or SBP (33 patients) [26]. PET/CT at
diagnosis identified 10 patients with at least two hyper-
metabolic lesions. Six of these patients progressed to
MM, confirming a diagnostic role for PET/CT in SP.
FDG-uptake was recently found to be correlated to the
tumor size [31]: FDG-avid lesions are generally larger
(41.4 mm) vs. FDG-negative lesions (23.5 mm) and the
statistical risk of progression was higher in these FDG-
avid lesions [31]. Based on these studies, the IMWG rec-
ommended PET/CT as part of the initial evaluation of
patients with SP [32].
Recommendations: In addition to the skeletal survey or
CT, MRI or PET/CT are needed to exclude the presence of
additional lesions and the use of at least one of these
examinations is mandatory (Grade 1A). Both are recom-
mended based on small prospective studies, while PET/CT
has additional prognostic value. Using both PET/CT and
MRI may offer complementary information. When both
PET/CT and MRI are not available, a WB-CT approach
can be used to exclude other lesions. (Grade 2C). To detect
additional soft tissue lesions, PET/CT is recommended for
patients with EMP (Grade 1B).
Prognostic factors
Progression of SP is defined as local recurrence, appear-
ance of additional plasmacytoma without signs of MM,
or a development of an overt MM. Different prognostic
factors have been identified for SP and this has led to
the proposal of different prognostic scoring methods
(Table 2). However, none of these have been thoroughly
validated and widely adopted.
Prognostic factors at diagnosis
EMP is usually indolent, in contrast to extramedullary
spread of MM which is associated with poor prognosis
[6, 7]. When compared to EMP, SBP has a worse prog-
nosis with increased progression rates to MM, although
the differences not always translate into a significant dif-
ference in overall survival (OS) [3, 4, 33–36] (Table 3).
At diagnosis, the presence of minimal BM infiltration by
clonal PCs is a strong prognostic factor. In a retrospect-
ive study, Warsame et al. found minimal BM infiltration,
assessed by immunofluorescence, in 24 out of 61
patients and this was associated with an inferior
progression-free survival (PFS 15 vs. 42 months for
patients without BM involvement) [37]. These results
were confirmed in recent studies in which flow cytome-
try was used to identify monoclonal PCs in BM samples
[10, 11]. Paiva et al. detected BM clonal PCs in 49% of
SBP and 38% of EMP patients. Seventy-one percent of
SBP patients with minimal BM involvement progressed
Table 2 Prognostic factors
Risk factor Progression free survival Reference
At diagnosis SBP vs. EMP Higher risk for progression to MM for SBP patients (progression rate of 65–84% at 10 years)
compared to EMP patients (25–35% at 10 years)
[36, 47]
Bone marrow plasmacytosis
detected by flow cytometry*
Minimal bone marrow plasmacytosis is associated with decreased progression-free survival [37]
Bone marrow plasmacytosis
detected by flow cytometry
About 70% of patients with minimal bone marrow plasmacytosis progress to MM with a
median time to progression of 26 months
[10, 11]
Serum SFLC ratio An abnormal serum FLC ratio is associated with a higher risk of progression to MM compared to a
normal SFLC ratio (44 vs. 26% at 5 years and 51 vs. 32% at 10 years)
[38]
Histological abnormalities Histologic score and degree of angiogenesis have prognostic value [40, 41]
At follow-up Persistence of a serum
monoclonal protein after
treatment
9% of progression for patients with resolved serum monoclonal protein vs. 71% of progression
for patients with persistent serum monoclonal protein.
[42]
*Only studied in the context of SBP
Abbreviations: SBP Solitary bone plasmacytoma, EMP Extrameddulary plasmacytoma, FLC Free light chain ration, MM multiple myeloma
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to MM with a median time to progression of 26 months,
compared to 8% for patients without BM involvement.
Of note, no significant differences were observed among
EMP cases, suggesting that BM involvement has
prognostic value specifically in SBP [11]. Similar
progression rates (72 vs. 12.5%) and time to progression
(26 months vs. not reached) were reported by Hill et al.,
who only evaluated patients with SBP [10].
Alike other PC disorders, such as monoclonal gammo-
pathy of undetermined significance (MGUS) and
smoldering MM (SMM), the serum free light chain
(SFLC) ratio is an independent prognostic factor in SP
for progression to MM when it is outside the normal
range (< 0.26 or > 1.65) [38, 39]. These results were
recently confirmed by Fouquet et al., who developed a
prognostic scoring method incorporating lesions on
PET/CT and an abnormal SFLC ratio at diagnosis as risk
factors for progression [26]. Other proposed prognostic
scoring methods include histologic scoring [40] and
assessment of the degree of angiogenesis [41].
Prognostic factors during follow-up
The presence of serum monoclonal protein at the time
of diagnosis has no prognostic value in SP. Conversely,
persistence of the serum monoclonal protein after
radiation therapy is a prognostic factor for progression
to MM among SP patients with detectable serum
monoclonal protein prior to treatment [23, 24, 34, 42–44].
For example, Wilder et al. reported a 10-year PFS of 29%
in patients with SBP whose serum monoclonal protein did
not disappear after radiotherapy, compared to 91% in pa-
tients whose serum monoclonal protein did resolve [42].
Interestingly, not only the presence of serum monoclonal
protein but also its levels yield prognostic information in
SBP. Dingli et al. proposed a prognostic scoring method
incorporating an abnormal SFLC ratio and a persistent
serum monoclonal protein level > 0.5 g/dl as adverse
prognostic factors. Using this method, three groups with a
different risk of progression could be identified [44]. Of
note, only the persistence of serum monoclonal protein
1 year after treatment has a clear prognostic value, as its
level can remain stable for several months before declin-
ing [44].
Recommendations: The rate of progression to MM is
higher in patients with SBP compared to patients with
EMP. At diagnosis, the presence of minimal BM infiltra-
tion by aberrant plasma cells, the presence of additional
hypermetabolic lesions on PET/CT, and an abnormal
SFLC ratio give prognostic information and should be
included in the initial assessment (Grade 1A). Persistence
of a serum monoclonal protein (determined by serum
electrophoresis and immunofixation) after initial radi-
ation therapy predict a higher risk of progression to MM.
Therefore, it is mandatory to monitor serum
electrophoresis and immunofixation after treatment com-
pletion (Grade 1A).
Treatment
Radiation therapy
Despite their locally destructive and aggressive charac-
teristics, clonal PCs are highly sensitive to radiation and
initial clinical trials confirmed the high response rates of
SP to radiotherapy [24, 34, 45, 46]. Caution is warranted
when analyzing older trials, because SP localization was
generally only determined via conventional radiography
and BM cytology. Therefore, many patients were likely
understaged in these trials.
The evidence for the effectiveness of radiation therapy
(Additional file 2: Table S2) is mainly based on retro-
spective studies as no prospective clinical trials in SP
comparing radiotherapy to best supportive care or to
chemotherapy have been reported. Ozsahin et al. retro-
spectively assessed the outcome in 206 patients with
SBP and 52 patients with EMP treated with radiotherapy
Table 3 Reported outcomes for patients presenting with
solitary plasmacytoma
Author N Local
recurrence, %
Overall survival,
% (years)
Progression-free
survival, % (years)
Nahi
et al. [4]
Total 191 NR 53% (8 years) 75% (2 years)
SBP 124 NR 56% (8 years) 65% (2 years)
EMP 67 NR 51% (8 years) 94% (2 years)
De Waal
et al. [36]
Total 100 0% 68% (10 years) 50% (15 years)
SBP 66 0% 64%(10 years) 30% (15 years)
EMP 34 0% 77% (10 years) 88% (15 years)
Katodritou
et al. [61]
Total 97 NR 78% (10 years) 59% (10 years)
SBP 65 NR 69% (10 years) 40% (10 years)
EMP 32 NR 86% (10 years) 50% (10 years)
Reed
et al. [48]
Total 84 8% 78% (5 years) 47% (5 years)
SBP 59 3% 76% (5 years) 56% (5 years)
EMP 25 20% 85% (5 years) 30% (5 years)
Kilciksiz
et al. [45]
Total 80 6% 73% (10 years) NR
SBP 57 6% 68% (10 years) NR
EMP 23 5% 89% (10 years) NR
Ozsahin
et al. [5]
Total 258 14% 55% (10 years) 35% (10 years)
SBP 206 14% 52% (10 years) 28% (10 years)
EMP 52 14% 72%(10 years) 74% (10 years)
Tsang
et al. [47]
Total 46 17% 65% (8 years) 50% (8 years)
SBP 32 22% NR 36% (8 years)
EMP 14 7% NR 84% (8 years)
Liebross
et al. [24]
SBP 57 4% 50% (10 years) 47% (10 years)
Liebross
et al. [3]
EMP 22 7% 50% (10 years) 68% (10 years)
NR not reported, SBP solitary bone plasmacytoma, EMP
extramedullary plasmacytoma
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alone (214 patients), radiotherapy combined with
chemotherapy (34 patients), or surgery alone (8 patients)
[5]. The 5-year OS, disease-free survival (DFS), and local
control rates were 74, 50, and 86% respectively in the
entire patient population. Radiotherapy was a favorable
prognostic factor for DFS and local control. The relapse
rate for patients receiving a radiation dose of 40–50 Gy
was 12% compared to 60% for patients who received no
radiotherapy. The local response rate to radiotherapy
exceeds 80–90% and appeared to be highest in tu-
mors < 5 cm in diameter. One study reported the use of
lower doses of radiotherapy and could not withhold a
dose-response relationship for doses > 35 Gy, even for lar-
ger tumors [47]. However, some studies did report a rela-
tionship between the initial tumor size and local control
rate. For example, Tsang et al. reported a 100% local con-
trol rate for SBP with a diameter < 5 cm compared to only
38% for SBP with a diameter > 5 cm. Whether large SBP
require a higher radiation dose or combined treatment for
effective local control, as these results suggest, remains to
be addressed in future clinical trials. Of note, the possible
relation between the administrated radiation dose and
tumor size and the local control of plasmacytoma remains
controversial as other retrospective studies did not con-
firm these findings [37, 48].
Based on the available clinical data, the recommended
treatment for most patients with SP is localized,
fractionated radiotherapy given at a dose of 40–50 Gy
over approximately 4 weeks [49]. Therapy is generally
given daily at a rate of 1.8–2.0 Gy per fraction. The
treatment field should include all the involved tissues
identified by imaging as well as a margin of healthy tis-
sue (at least 2 cm). This margin is needed because the
risk of tumor extension outside the initial radiation
portal can enhance disease recurrence. In the case of
SBP affecting vertebrae, the margin should include at
least one uninvolved vertebra on either side.
Surgery
In many instances, patients have had surgery, with
complete or partial tumor removal, as part of the
diagnostic procedure. Apart from the diagnostic
approach, the indication of surgery are fixation of
fractures, decompressive laminectomy, or spine
stabilization. The introduction of modern spinal fix-
ation and stabilization methods, such as vertebro-
plasty and kyphoplasty, allows for a surgical solution
for patients who develop vertebral fractures, vertebral
instability, neurological complications, or a combin-
ation of these. Radiotherapy can be delayed until after
surgery but it is still required because tumor excision
without subsequent radiotherapy results in a very
high rate of local recurrence [46].
Chemotherapy
The role of adjuvant chemotherapy after radiation ther-
apy in the treatment of SP remains controversial
precluding a definite recommendation. In a study on 32
SP patients, Holland et al. observed that adjuvant
chemotherapy did not affect the incidence of progression
to MM (53% for SBP and 36% for EMP) but did delay
progression from 29 to 59 months [43]. Similarly, Aviles
et al. reported improved outcome in a small randomized
prospective clinical trial on SBP when patients received
adjuvant melphalan and prednisolone for 3 years [50].
After a median follow-up of 8.9 years, OS was 88% for
patients receiving adjuvant chemotherapy, compared to
46% in the control group. Of note, BM infiltration in
these patients was assessed by morphology alone, which
does not have the sensitivity required to detect minimal
infiltration. Conversely, other studies indicate that adju-
vant chemotherapy for SP has no benefit [51, 52]. Also,
autologous stem cell transplantation has been evaluated
in high-risk SP patients but, although the initial results
were promising, the small number of patients in this
study precludes drawing definitive conclusions [53].
Some of the authors of these guidelines propose the use
of adjuvant chemotherapy for bulky SP (> 5 cm), but this
approach is not supported by previous studies. Similar
to other plasma cell precursor entities (MGUS and
SMM), bisphosphonates are recommended for those
patients with confirmed osteoporosis on dual-energy
X-ray absorptiometry scan in doses used for patients
with osteoporosis [54]. Systemic use of bisphosphonates
has not been studied in the context of SP but does not
delay tumor progression in the SMM setting [55]. They
can be considered for patients with a threatening
fracture due to a SBP.
Recommendations: Radiation therapy is the standard
treatment for SBP and EMP (Grade 1A). A total fraction-
ated dose of 40–50 Gy should be given, and a margin of
at least 2 cm should be employed (Grade 1A). For pa-
tients with SBP, surgery should be reserved for the treat-
ment of pathological fractures, neurological
complications, or lesions with a high chance for fracture
or instability. For patients with EMP, surgery might be
able to resect large and well-defined masses but should
be followed by radiotherapy. Due to the limited available
data, adjuvant chemotherapy is not recommended for
patients with SP. Adjuvant chemotherapy can be consid-
ered for patients with persistent disease, based on PET/
CT, after initial radiotherapy (Grade 2C).
Response assessment
There are currently no guidelines for the assessment of
treatment responses in SP. We suggest that the defini-
tions that are currently applied in MM can be used in
the setting of SBP, while RECIST criteria can be used for
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assessing treatment responses in EMP [56, 57] (Table 4).
For patients who have detectable serum monoclonal
protein at diagnosis, the response can be assessed similar
to the uniform IMWG response criteria for MM [58].
Serum and urine electrophoresis and immunofixation as
well as serum free light chain analysis should be regu-
larly performed during follow-up. As discussed, serum
monoclonal protein can remain stable for several
months before declining. In case of increasing serum
monoclonal protein levels or the appearance of
myeloma-associated end-organ damage, a new bone
marrow sample should be taken in order to quantify the
PC infiltration and to detect genetic abnormalities. The
sensitivity of PET/CT for the evaluation of treatment re-
sponses is higher than that of MRI. A persistent high
uptake on 18F-FDG PET/CT indicates the presence of
residual disease. Low tracer uptake at irradiated sites can
be due to bone remodeling and is not always associated
with a poor prognosis. Preferentially, the same imaging
technique should be used for diagnosis and for the
evaluation of treatment responses.
Recommendations: Treatment response should be
assessed according to the IMWG criteria for patients
with measurable serum/urine parameters (Grade 1B),
although serum monoclonal protein can remain stable
for several months. For soft tissue lesions, these criteria
should be combined with the RECIST criteria (Grade
2C). During further follow-up of the disease, the same
imaging (preferentially a whole body technique) method
should be used, but one should be aware that the sensi-
tivity of PET/CT is higher than that of MRI.
Future direction for clinical research
The current guidelines in SP are based on small-scale
studies because prospective clinical trials are hampered
by the low incidence of SP. Still, larger studies are
needed to further establish and refine the current diag-
nosis and treatment guidelines. Large prospective clin-
ical trials to evaluate addition of systemic treatment
(including novel agents) to radiation therapy are needed
to define the optimal treatment approach of patients
presenting poor prognostic factors such as tumor size
and the presence of clonal BMPCs. Moreover, different
imaging techniques should be compared for SP diagnosis
and follow-up. While low-dose WB-CT is used in MM,
studies investigating this technique in SP are still lack-
ing. At this time, PET/CT is considered the imaging
technique of choice, but the introduction of diffuse
weighted MRI could improve the ability of MRI to dis-
criminate between active and inactive lesions. A multi-
center SWOG trial (ClinicalTrials.gov: NCT00109889)
comparing PET/CT with MRI in SP was closed in 2007
but its results are still unknown. In 2017, there is no sci-
entific evidence that patients with an initial BM infiltra-
tion require additional therapy, although they are at high
risk of progression, particularly those with aberrant
phenotype. Accordingly, in smoldering MM (SMM) a
high-risk group of patients with > 70% risk of progres-
sion to MM in 2 years could be identified by immuno-
phenotyping of aberrant PCs. It has been shown that
early treatment prevents progression to MM in these
high-risk SMM patients [59]. Mateos et al. demonstrated
not only a superior PFS, but also OS in patients treated
with lenalidomide-dexamethasone, as compared to
observation [60].
Although it is currently unknown, whether such a para-
digm is applicable to SBP, the rate of progression to MM
in SBP patients with occult BM infiltration is comparable
to that observed in high-risk SMM. Therefore, a random-
ized trial with similar design comparing treatment for a
limited period vs. observation seems justified. A regular
follow-up by blood and urine testing is required for these
patients and a new BM aspiration and biopsy should be
performed when a progression is suspected.
Advanced and sensitive techniques for the detection of
monoclonal PCs are being developed and are already
used in daily practice to detect MRD in the follow-up of
MM. However, prospective trials with these new
techniques in the diagnosis and follow-up of SP are lack-
ing. Multiparametric flow cytometry uses a standard set
of monoclonal PC-associated markers, is quantitative,
includes an internal quality control of the sample
Table 4 Definition of treatment responses
Complete response (CR) Complete disappearance of all previously observed abnormalities on radiographic imaging. For patients with a secretory
plasmacytoma, a disappearance of monoclonal protein from serum and/or urine. For SBP, the initial radiological abnormalities
on MRI or CT should regress or stabilize during an observation time of at least 12 months to fulfill the requirements for a CR.
For EMP, the disappearance of soft tissue mass is required for the definition of CR
Very good partial
response (VGPR)
A CR with regard to clinical and radiological signs, but with a positive immunofixation or ≥ 90% reduction in serum monoclonal
protein plus urine monoclonal protein level < 100 mg/24 h.
Partial response (PR) A ≥ 50% decrease in serum and/or urine monoclonal protein. For non-secretory SP, radiological features (MRI/CT) or local
assessment is needed. In EMP patients, a 30% decrease in the diameter of target lesions should be observed.
Stable disease (SD) Insufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD.
Progressive disease (PD) The development of new lesions or an increase of at least 20% in the size of existing lesions, the apparition of a myeloma
defining event, and finally an increase of > 25% from lowest response value in serum and/or urine monoclonal protein.
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cellularity and hemodilution, and is applicable for
virtually every patient. Also, PCR-based techniques such
as quantitative allele-specific oligonucleotide PCR
(ASO-qPCR) and next-generation sequencing of VDJ
sequences remain unexplored in SP.
While FISH studies have confirmed that SP is part of
the spectrum of plasma cell disorders, they could not
identify prognostic subgroups as in MM. Future compar-
isons between monoclonal plasma cells obtained from
SP and BM (if a minimal infiltration is present) would
allow identification of additional, secondary genetic
aberrations that drive tumor progression. More ad-
vanced techniques such as single nucleotide polymorph-
ism (SNP) or gene expression arrays will also contribute
to a better understanding of the tumor biology.
Inclusion of more patients in these studies will facilitate
prognostic stratification and identification of patients
with a high risk of progression that could benefit from a
systemic treatment to postpone disease progression.
As for prognostic scoring methods, only minimal BM
aberrant plasmacytosis has been extensively validated as
a prognostic factor in SBP for progression to MM. The
identification and validation of additional risk factors,
such as those used in SMM, is of interest to better iden-
tify those patients that might benefit from adjuvant ther-
apy or to delay progression to MM.
Finally, additional clinical trials to address the role of
adjuvant chemotherapy for SP are needed. Of note, the
treatment approaches in all reported studies included
conventional chemotherapy. Studies with novel potent
MM agents, such as proteasome inhibitors (bortezomib,
ixazomib, and carfilzomib), immunomodulatory agents
(thalidomide, lenalidomide, and pomalidomide) or mono-
clonal antibodies (elotuzumab and daratumumab)
are currently lacking. Focus on those patients who are at
high risk for progression to MM (i.e., the detection
of BM clonal PC cells by flow cytometry, more than one
hypermetabolic lesion at PET/CT plus abnormal FLC ra-
tio, residual paraprotein after radiation therapy, and
bulky tumor mass > 5 cm) is warranted.
Conclusion
Solitary plasmacytoma belongs to a spectrum of plasma
cell disorders and is defined by a single mass of mono-
clonal plasma cells that can be found in the bones or in
the extramedullary regions. We updated the recommen-
dations on the diagnosis and management and proposed
a new definition of response assessment. While radio-
therapy remains the recommended treatment, several
risk factors for early progression to multiple myeloma
have been identified. Further studies evaluating adjuvant
treatment regimens (based on novel agents) are urgently
needed for these high-risk patients.
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